CURRICULUM VITAE

LAST UPDATE: January 2026

NAME: Matthew Matasar, MD, MS

PRESENT TITLE: Division Chief, Blood Disorders, Rutgers Cancer Institute
Professor, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey

EDUCATION:

A. Undergraduate

Harvard College
Cambridge, MA
Bachelor of Arts/Sciences, History and Philosophy of Science and Technology 1992-1996

B. Graduate and Professional

Harvard Medical School

Boston, MA
Medical Doctor 1996-2000

Mailman School of Public Health
Columbia University
New York, NY
Master of Science, Biostatistics 2003-2005

POSTGRADUATE TRAINING:

A. Internship and Residencies

New York-Presbyterian (Columbia Campus)
New York, NY
Intern, Internal Medicine 2000-2001

New York-Presbyterian (Columbia Campus)
New York, NY
Resident, Internal Medicine 2001-2003

New York-Presbyterian (Columbia Campus)
New York, NY
Chief Resident, Internal Medicine 2003-2004

Columbia University Medical Center
New York, NY

Post-Doctoral Fellow (T-32 Training Grant),
Cancer Epidemiology and Prevention 2003-2005

B. Fellowship Training
Memorial Sloan- Kettering Cancer Center
New York, NY
Fellow, Medicine Hematology and Oncology 2005-2008

C. Postdoctoral Appointments: None

MILITARY: None

ACADEMIC APPOINTMENTS:

Instructor, Clinical Medicine
New York-Presbyterian (Allen Campus)
New York, NY
2004-2005

Assistant Member (Level 1)
Memorial Sloan Kettering Cancer Center (MSKCC)
New York, NY
2009-2015

Assistant Member
Memorial Sloan-Kettering Cancer Center
New York, NY
2015-2019

Assistant Professor of Medicine
Weill Cornell Medical College
New York, NY
2015- 2020

Associate Member
Memorial Sloan Kettering Cancer Center
New York, NY
2019-2022

Associate Professor of Medicine
Weill Cornell Medical College
New York, NY
2020-2022

Professor
Department of Medicine and Division of Blood Disorders
Rutgers Robert Wood Johnson Medical School
2022- Present

HOSPITAL APPOINTMENTS:

Instructor in Medicine
Columbia University Medical
2003-2005

Assistant Member and Attending Physician
Memorial Hospital for Cancer and Allied Diseases
2008- 2019

Associate Member and Attending Physician
Memorial Hospital for Cancer and Allied Diseases
2019-2022

Attending Physician
Robert Wood Johnson University Hospital
2022-Present

Chief, Division of Blood Disorders
Rutgers Cancer Institute, New Brunswick, NJ
2022-Present

INSTITUTIONAL/HOSPITAL AFFILIATION:

Rutgers Cancer Institute (Primary)
Robert Wood Johnson University Hospital
Memorial Hospital for Cancer and Allied Diseases
Weill Cornell Medical College

PRIVATE PRACTICE: N/A

LICENSURE:

NJ Medical Doctor- 25MA10303100 (Issued 10/15/2024)
NY Medical Doctor- 227471 (Issued 06/30/2024)
DEA number- FM0893568
NPI number- 1629237987

DRUG LICENSURE: N/A

CERTIFICATION:

American Board of Internal Medicine, #222694, 2003-2013
Medical Oncology Certification, #222694, 2008-Present

MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:

A. Memberships – National/Regional

Board Certified, American Board of Internal Medicine	2003-Present
Member, Residency Selection Committee, New York Presbyterian (Columbia Campus)	2003-2005
Member, American Society of Clinical Oncology	2005- Present
Member, American Society of Hematology	2007- Present
Board Certified, Medical Oncology	2008- Present
Member, American Society of Blood and Marrow Transplantation	2010- Present
Member, MSH 2023 Symposium and Ad Board	2022- Present
AstraZeneca Hematology Ambition Steering Committee	2023- Present
Bristol Myers Squibb Worldwide Golcadomide ASH Ad Board	2024
Arvinas ASH Ad Board	2024

B. Offices and Committee Assignments

See Service on Major Committees, below

HONORS AND AWARDS:

Leukemia & Lymphoma Society Quality of Life Award	2024
John Harvard Scholar, Harvard College	1992-1996
Phi Beta Kappa, Harvard College	1995
Inductee, Aesculapean Society, Harvard Medical School	1999
Honorable Mention, Teaching Resident of the Year, Columbia University College of Physicians and Surgeons	2002
Recipient, Mortimer Lacher Fellowship, Lymphoma Foundation	2006-2007
Nominee, Celgene Award for Clinical Research in Hematology	2007
Hematology Attending Teaching Award,	

Memorial Sloan Kettering Cancer Center 2010
Hematology Attending Teaching Award,
Memorial Sloan Kettering Cancer Center 2014
Dr. John J. Kenny Award, Leukemia Lymphoma Society 2017
Recognition of Exemplary Service during the
COVID-19 Pandemic 2020

- COVID HICS – Bergen
- COVID Vaccine Clinic: Volunteer
- New York State COVID Care: Volunteer

BOARDS OF DIRECTORS/TRUSTEES POSITIONS:

Board of Trustees, Trustee Member,
Leukemia and Lymphoma Society (Long Island Chapter) 2016-2018
Board of Trustees, Trustee Member,
Leukemia and Lymphoma Society (NJ Chapter) 2018- Present
Board Member, Oncology
MJH Life sciences 2020- Present
Consultant
Radiolab 2018- Present

PRESENTATIONS:

1. Satellite Symposium: Roche Korea, Recent Insights on DLBCL Treatment: Focused on Polatuzumab and Glofitamab, March 2026
2. DAVA Oncology Regional Colloquium on Lymphoma, February 13th, 2026, Washington DC
3. 49th Annual Conference of the Mumbai Hematology Group, January 24th-26th, 2026, Mumbai, India,
4. Boehringer Ingelheim Global TcE Alliance, January 27, 2026, Ingelheim, Germany
5. Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Symposium, ASH Annual Meeting, December 5, 2025
6. Clinical Care Options (CCO) Lymphoma FL Bispecifics program series entitled, "A Multidisciplinary Roadmap for Integrating Bispecific Antibodies to Enhance Outcomes in Follicular Lymphoma Care," August 2025
7. Genentech/Roche post-EHA/ICML Meeting, Virtual Lecture: Updated Data of Mosunetuzumab in FL Treatment, July 2025
8. Reach MD, Virtual Interview: Optimizing CAR T-Cell Therapy in 2L R/R LBCL, June 2025
9. *e*cancer, Virtual Interview, Polatuzumab Vedotin, Rituximab, Gemcitabine And Oxaliplatin (Pola-R-Gemox) For Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl): Results From The Randomized Phase Iii Polargo Trial, June 2025
10. The Healthbook Company Ltd, Virtual Interview, Polatuzumab Vedotin, Rituximab, Gemcitabine And Oxaliplatin (Pola-R-Gemox) For Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl): Results From The Randomized Phase Iii Polargo Trial, June 2025
11. European Hematology Association (EHA) Congress 2025, Keynote Speaker, Milan: Novel Epigenetic and Targeted Therapies in Relapsed/Refractory Follicular Lymphoma: Bridging Science and Patient Outcomes, June 2025
12. Kite Advisory Summit on Strategies and CAR T approaches, Advisor/Speaker, Kite- A Gilead Company, May 2025
13. Expert Talks with Professor Matthew Matasar, "How do I treat 1st line of DLBCL?", Roche, April 2025
14. Best Practices in Lymphoma, "Managing ADC-related Toxicities in DLBCL," DAVA Oncology, Speaker, April 2025

15. Whistler Global Summit on Hematologic Malignancies, Speaker, April 2025
16. Cancer Game Changers: An Exclusive Evening of Canner Innovations, Panel Discussion, Rutgers Cancer Institute Philanthropy, March 2025
17. Update on Treatment Approached in Diffuse Large B-Cell Lymphoma (DLBCL): Where Are We and Where Are We Heading? Miami Cancer Institute: Global Summit on Immunotherapies for Hematologic Malignancies, March 2025
18. Lymphoid Malignancies Poster, "Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective," ASH Annual Meeting, December 2024
19. Fall Rutgers Health Leadership Council meeting, October 2024
20. CTMI-3 (0006): Matthew Matasar, MD- Hybrid Community Oncology Forums: CAR T Cell Therapies for B Cell Lymphoma in the Community Setting - Empowering Peer-to-Peer Education, September 2024
21. Communicating with Patients While Navigating the New Landscape of Diffuse Large B-cell Lymphoma (DLBCL), Association of Cancer Care Centers (ACCC), August 2024
22. 8th Annual Live Medical Crossfire®: Hematologic Malignancies, July 2024
23. ASCO 2024: Interview With Oncology Learning Network, June 2024
24. CME satellite symposium at the 2024 ASH Annual Meeting, June 2024
25. Bispecific Antibodies In Diffuse Large B-Cell Lymphoma - Indication, Coordination, Transitioning back to community practice, April 2024
26. LLS Light the Night, Executive Lauch Breakfast, July 2023
27. 5th Annual Immunotherapies Summit For Hematologic Malignancies, Miami Cancer Institute, March 2024
28. T-cell and NK-cell based immunotherapies for Lymphoid Malignancies," Milan, September 2023
29. Managing the practicalities of CAR T-cell therapies in patients with R/R MCL: Current considerations and future strategies, TouchIME, September 2023
30. Bridging the Legacy to the Future of Hematologic Malignancies at Rutgers Cancer Institute, June 2023.
31. "Community Practice Patterns Inform Strategies to Enhance Clinical Management of MCL and DLBCL: A Multi-Year Initiative," Continuing Medical Education (CME) program, February 2023.
32. 20th Malaysia Society of Hematology (MSH) Annual Scientific Meeting, 2023.
33. Follicular Lymphoma, CORE (Community Oncology Research Evaluations) Report: Strategic Insights into Follicular Lymphoma (FL) From Community Oncologists, February 27, 2023.
34. Great Debates & Updates in Hematologic Malignancies, April 2023, New York.
35. "Using loncastuximab tesirine and tafasitamab/lenalidomide in patients with relapsed/refractory diffuse large B-cell Lymphoma." Targeted Oncology, Case-Based Roundtable, July 2023.
36. Precision Medicine Perspectives focusing on FL, November 2022
37. Systemic Therapy for Relapsed/Refractory DLBCL, Targeted Oncology HealthCare Research & Analytics, New York City, November 17, 2022.
38. GLG Teleconference on Lymphoma – Pre-ASH, December 2022.

SERVICE ON MAJOR COMMITTEES:

A. International

Late Effects of Childhood Cancer
Member,
International Guideline harmonization Group — June 2021-Present

B. National

Steering Committee
Member
Lymphoma Connect — 2018- Present

Steering Committee
Member
TheMednet.Org — 2018- Present

Quality Committee
Member
American Society of Hematology

Advisory Board
Member, Abbvie, Allogene, Arvinas, Beigene, Genmab
Genentech, Merck, Novartis, Roche, Pfizer, Pierre Fabre — 2022-Present

C. Medical School/University

Medicine Steering Committee, Committee Member	2013- Present
Fertility Preservation Committee, Committee Member	2013- Present
Clindoc Committee, Committee Member	2011-2012
BMT QA Committee, Committee Member	2010-2017
MSKCC Diversity Committee, Committee Member	2017- Present
MSKCC Clinical Competence, Committee Member	2016- Present
MSKCC Executive Council, Committee Member	2018- Present
MSKCC Research Council, Committee Member	2020- Present

D. Regional: N/A

E. Editorial Boards

Associate Editor
Editor for Lymphoma
American Society of Hematology — 2021- Present

Editorial Board, Oncology — 2016- Present

Editorial Review Board,
Journal of Hematologic Malignancies — 2011- Present

F. *AdHoc* Reviewer

Peer Review, Value in Health / Editorial Board	2005- Present
Ad Hoc Reviewer, Value in Health	2005
Peer Review, Blood / Editorial Board	2006- Present
Ad Hoc Reviewer, Blood	2006- Present
Reviewer Blood Advances	2020-Present
Peer Review, Leukemia and Lymphoma	2007
Ad Hoc Reviewer, Leukemia and Lymphoma	2007- Present
Peer Review, Cancer	2013- Present
Peer Review, Journal of Hematologic Malignancies	2013
Medical Reviewer, Lymphoma Research Foundation, Lymphoma Survivorship Factsheet	2017
Ad Hoc Reviewer, Leukemia and Lymphoma	2018- Present
Ad Hoc Reviewer, Cancer	2013- Present
Ad Hoc Reviewer, Journal of Clinical Oncology	2013- Present
Peer Reviewer, Journal of the National Cancer Institute, and Leukemia and Lymphoma	2019-Present
Ad Hoc Reviewer for Lancet Oncology	2021-Present

SPONSORSHIP (Primary Mentorship) OF POSTDOCTORAL FELLOWS:

Resident Mentor for house staff from WCMC
Site/Position: WCMC and other institutions
Type of Supervision: Clinical/Teaching 2008- Present

Fellow Mentor, MSKCC
Site/Position: MSKCC
Type of Supervision: Clinical/Teaching 2008- Present

Dr. Ildefonso Rodriguez-Rivera
Site/Position: MSKCC
Type of Supervision: Junior faculty mentor

Dr. Lorenzo Falchi
Site/Position: MSKCC
Type of Supervision: Junior faculty mentor

TEACHING RESPONSIBILITIES:

A. Lectures or Course Directorships

Teaching, WCM House Staff	2008-2022
Teaching, MSKCC DOM Grand Rounds	2008-2022
Teaching, House Staff Lectures at NYP	2008-2022
Teaching, MSKCC Grand Rounds	2008-2022
Teaching, MSKCC Fellows	2008-2022

B. Clinical Training

Physical Diagnostics, WCMC Medical Students	2014
Clinical Education, Lymphoma House Staff WCMC	2008- 2022
Clinical Education, Lymphoma MSK Fellows	2008- 2022
Clinical Preceptor , WCMC Medical Students	2021- 2022
In/out-patient clinical precepting RWJBH Hospital	2022- Present

GRANT SUPPORT:

A. Principal Investigator

1. Characterization of poor-risk relapsed Non Hodgkin Lymphoma subtypes for precision medicine – Renewal (2022-2024)
2. Tissue and Functional Assessment of Myocardial Injury in HL Survivors, MSK IRB 13-034, LLS TRP, PI – Collaboration between MSKCC and WCMC (WCMC Dr. Jonathan Weinsaft, co-PI), 2013-2016
3. A Single Arm, Safety and Efficacy Study of Ofatuumab in combination with ICE or DHAP Chemotherapy in Relpased or Refractory Aggressive Lymphoma Prior to Autologous Stem Cell Transplantation, MSK IRB 09-082, PI, 2011-2013
4. Ofatumumab versus Rituximab Salvage Chemoimmunotherapy Followed by ASCT in Relapsed or Refractory DLBCL, MSK IRB 11-079, PI, 2012-2015
5. Comskils Survivorship Transitioning, MSK IRB 11-180, R01, Co-PI, 2011- Present
6. Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders, MSK IRB 00-069, Co-PI, 2010-Present
7. Safety and Immunogenicity of Herpes Zoster Vaccine 1437173A in Autologous Hematopoietic Cell Transplant Recipients, MSK IRB 10-027, Co-PI, 2010-2014
8. A randomized double-blind placebo-controlled phase 3 study of SGN-35 and best supportive care versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant, MSK IRB10-175, Co-PI, 2010-2015
9. A phase III double-blind randomized placebo-controlled multicenter clinical trial to study the safety tolerability efficacy and immunogenicity of V212 [shingles vaccine] in recipients of autologous stem cell transplant. MSK IRB 11-065, Co-PI, 2011-2013
10. Survey to Assess International Travel Patterns and Health Preparations of
11. Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center, MSK IRB 11-176, Co-PI , 2011-2012

12. A Phase III, Randomized, Observer-blind, Placebo Controlled, Multicenter Clinical Trial to Assess the Prophylactic Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster (gE/AS01B) Vaccine when Administered Intramuscularly on a Two Dose Schedule to Adult Autologous Hematopoietic Stem Cell Transplant (HCT) Recipients, MSK IRB 13-054, Co-PI, 2013-2016
13. A Phase Ib/II Study Evaluating the Safety, Tolerability and Anti-tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination with Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-cell Lymphoma. MSK IRB 15-170, PI, 2015-Present
14. An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of BTCT4465A In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia. MSK IRB 16-182, PI, 2016-Present
15. 18-230 (GO39942: A Phase III, Multicenter, Randomized, Double- Blind, Placebo-Controlled Trial Comparing The Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP, 2018-Present
16. (RCHOP) in Previously Untreated Patients with Diffuse Large B-cell Lymphoma), PI, 17-359 (Real World Practice Efficiency with Subcutaneous Rituximab Analysis), PI, 2018-Present
17. 16-873 (A Phase III, Randomized, Double-Blind, Controlled, Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination with Standard Immunochemotherapy versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-4), PI and National PI, 2017- Present
18. 15-236 (A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination with Rituximab in Patients with Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3), PI and National PI, 2017- Present
19. 14-107 (A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study), PI, 2018- Present
20. 18-457 (Retrospective analysis of the use o R-GemOx in patients with relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma at MSKCC), PI, 2018-Present
21. 19-322 (A Phase I open-label, multicenter study evaluating the safety and pharmacokinetics of escalating doses of IGM-2323 in subjects with relapsed/refractory non-Hodgkin lymphoma), PI, 2019-Present
22. 20-031 (Phase III Open-Label multicenter randomized study evaluating the safety and efficacy of polatuzumab vedotin in combination with rituximab plus gemcitabine plux oxaliplatin (R-GEMOX) versus R-GEMOX alone in patients with relapsed/refractory diffuse large B-cell lymphoma), PI and international steering committee Chair, 2020-Present
23. ACE-LY 312 (A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma), in collaboration with WCMC, International Steering Committee member, 2020-Present

<u>Clinical Trial Studies at the Rutgers Cancer Institute of New Jersey:</u>

1. A phase 2 study of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular and marginal zone lymphoma
2. A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an anti CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)
3. A Phase 3 Randomized Clinical Study of MK-4280A coformulated favezelimab MK-4280 plus pembrolizumab MK-3475 Versus Physician s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)
4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects <=75 Years with Previously Untreated Non- Germinal Center Diffuse Large B-Cell Lymphoma

5. A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination with Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)
6. A Phase Ib, Open-Label, Dose-Escalation, Multicenter Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous Glofitamab Following Obinutuzumab Pretreatment In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
7. A Phase 1 Study of TJ011133 Administered Alone or in Combination with Pembrolizumab or Rituximab in Subjects with Relapsed/Refractory Advanced Solid Tumors and Lymphoma
8. A Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas.
9. A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma.
10. A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission.
11. A Phase II/III Randomized Study of R-miniCHOP With or Without Oral Azacitidine (CC-486) in Participants Age 75 years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas With MYC and BCL2 and/or BCL6 Rearrangements.
12. A Phase Ib, Open-Label, Dose-Escalation, Multicenter Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous Glofitamab Following Obinutuzumab Pretreatment In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma.
13. A Phase 1 Study of TJ011133 Administered Alone or in Combination with Pembrolizumab or Rituximab in Subjects with Relapsed/Refractory Advanced Solid Tumors and Lymphoma.
14. A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies.
15. An Open-Label, Multi-center Phase I Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 bispecific Monoclonal Antibody, in Patients with CD20+ B-cell Malignancies Previously Treated with CD20 Directed Antibody Therapy.

B. Co-Investigator Studies
1. Systematic Light Exposure for Fatigue in Stem Cell Transplant Survivors: T-32 Training Grant - $725,495 for five Years (01/01/2016-12/31/2020).
2. K-30 Training Grant- 2003-2005, PI- Melissa D. Begg, Sc.D.
3. Communication Skills Intervention to Promote Transition into Survivorship: 525,659 for seven years (07/01/2010-06/30/2016).
4. Lymphoma and Leukemia Society- $600,000 for four years (10/01/2013-09/31/2016).

PUBLICATIONS:

A. Refereed Original Article in Journal
1. Neugut AI, **Matasar M**, Wang X, McBride R, Jacobson JS, Tsai WY, Grann VR, Hershman DL. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006 May 20;24(15):2368-75. doi: 10.1200/JCO.2005.04.5005. Epub 2006 Apr 17. PMID: 16618946.

2. **Matasar MJ**, Ritchie EK, Consedine N, Magai C, Neugut AI. Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States. Eur J Cancer Prev. 2006 Aug;15(4):367-70. doi: 10.1097/00008469-200608000-00011. PMID: 16835508.

3. **Matasar MJ**, Ritchie EK, Consedine N, Magai C, Neugut AI. Incidence rates of the major leukemia subtypes among US Hispanics, Blacks, and non-Hispanic Whites. Leuk Lymphoma. 2006 Nov;47(11):2365-70. doi: 10.1080/10428190600799888. PMID: 17107911.

4. **Matasar MJ**, Shi W, Silberstien J, Lin O, Busam KJ, Teruya-Feldstein J, Filippa DA, Zelenetz AD, Noy A. Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification. Ann Oncol. 2012 Jan;23(1):159-166. doi: 10.1093/annonc/mdr029. Epub 2011 Mar 17. PMID: 21415238.

5. Moskowitz CH, **Matasar MJ**, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, Horwitz S, Moskowitz AJ, Noy A, Palomba L, Perales MA, Portlock C, Straus D, Maragulia JC, Schoder H, Yahalom J. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012 Feb 16;119(7):1665-70. doi: 10.1182/blood-2011-10-388058. Epub 2011 Dec 19. PMID: 22184409; PMCID: PMC3790950.

6. Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, **Matasar MJ**, Noy A, Palomba ML, Portlock CS, Straus DJ, Graustein T, Zelenetz AD, Moskowitz CH. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013 Feb 1;31(4):456-60. doi: 10.1200/JCO.2012.45.3308. Epub 2012 Dec 17. PMID: 23248254; PMCID: PMC3862960.

7. **Matasar MJ**, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh RP, Lisby S, Moskowitz CH. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 2013 Jul 25;122(4):499-506. doi: 10.1182/blood-2012-12-472027. Epub 2013 May 21. PMID: 23692856; PMCID: PMC3724189.

8. Mehta N, Maragulia JC, Moskowitz A, Hamlin PA, Lunning MA, Moskowitz CH, Zelenetz A, **Matasar MJ**, Sauter C, Goldberg J, Horwitz SM. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):664-70. doi: 10.1016/j.clml.2013.07.005. Epub 2013 Sep 11. PMID: 24035712.

9. Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, Goldberg J, Zelenetz AD, Hamlin PA, **Matasar MJ**, Maragulia J, Giralt SA, Perales MA, Moskowitz CH, Sauter CS. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014 Dec;20(12):2004-9. doi: 10.1016/j.bbmt.2014.08.019. Epub 2014 Aug 28. PMID: 25175794; PMCID: PMC5480286.

10. Mikati T, Griffin K, Lane D, **Matasar M**, Shah MK. International travel patterns and travel risks for stem cell transplant recipients. J Travel Med. 2015 Jan-Feb;22(1):39-47. doi: 10.1111/jtm.12166. Epub 2014 Oct 17. PMID: 25327693.

11. **Matasar MJ**, Ford JS, Riedel ER, Salz T, Oeffinger KC, Straus DJ. Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood. J Natl Cancer Inst. 2015 Feb 24;107(4):djv018. doi: 10.1093/jnci/djv018. PMID: 25717170; PMCID: PMC6281032.

12. Welch MR, Sauter CS, **Matasar MJ**, Faivre G, Weaver SA, Moskowitz CH, Omuro AM. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide. Leuk Lymphoma. 2015 Feb;56(2):361-7. doi: 10.3109/10428194.2014.916800. Epub 2014 Jun 27. PMID: 24745937.

13. Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, **Matasar MJ**, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015 Feb 26;125(9):1403-10. doi: 10.1182/blood-2014-10-604561. Epub 2015 Jan 7. PMID: 25568347; PMCID: PMC4342354.

14. Straus DJ, Hamlin PA, **Matasar MJ**, Lia Palomba M, Drullinsky PR, Zelenetz AD, Gerecitano JF, Noy A, Hamilton AM, Elstrom R, Wegner B, Wortman K, Cella D. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not

eligible for autologous stem cell transplantation. Br J Haematol. 2015 Mar;168(5):663-70. doi: 10.1111/bjh.13195. Epub 2014 Oct 15. PMID: 25316653.

15. Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, Kumar A, **Matasar M**, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Shukla N, Steinherz P, Straus D, Trippett T, Younes A, Zelenetz A, Moskowitz CH. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015 Mar;16(3):284-92. doi: 10.1016/S1470-2045(15)70013-6. Epub 2015 Feb 13. PMID: 25683846.

16. Sauter CS, **Matasar MJ**, Meikle J, Schoder H, Ulaner GA, Migliacci JC, Hilden P, Devlin SM, Zelenetz AD, Moskowitz CH. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015 Apr 16;125(16):2579-81. doi: 10.1182/blood-2014-10-606939. Epub 2015 Mar 10. PMID: 25758829; PMCID: PMC4624450.

17. Banerjee SC, **Matasar MJ**, Bylund CL, Horwitz S, McLarney K, Levin T, Jacobsen PB, Parker P, Astrow A, Kissane DW. Survivorship care planning after participation in communication skills training intervention for a consultation about lymphoma survivorship. Transl Behav Med. 2015 Dec;5(4):393-400. doi: 10.1007/s13142-015-0326-z. Epub 2015 Jun 2. PMID: 26622912; PMCID: PMC4656222.

18. Schöder H, Zelenetz AD, Hamlin P, Gavane S, Horwitz S, **Matasar M**, Moskowitz A, Noy A, Palomba L, Portlock C, Straus D, Grewal R, Migliacci JC, Larson SM, Moskowitz CH. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. J Nucl Med. 2016 May;57(5):728-34. doi: 10.2967/jnumed.115.166769. Epub 2015 Dec 30. PMID: 26719374; PMCID: PMC4854760.

19. Kelvin JF, Thom B, Benedict C, Carter J, Corcoran S, Dickler MN, Goodman KA, Margolies A, **Matasar MJ**, Noy A, Goldfarb SB. Cancer and Fertility Program Improves Patient Satisfaction With Information Received. J Clin Oncol. 2016 May 20;34(15):1780-6. doi: 10.1200/JCO.2015.64.5168. Epub 2016 Apr 4. PMID: 27044937; PMCID: PMC4966338.

20. Pun SC, Plodkowski A, **Matasar MJ**, Lakhman Y, Halpenny DF, Gupta D, Moskowitz C, Kim J, Steingart R, Weinsaft JW. Pattern and Prognostic Implications of Cardiac Metastases Among Patients With Advanced Systemic Cancer Assessed With Cardiac Magnetic Resonance Imaging. J Am Heart Assoc. 2016 May 4;5(5):e003368. doi: 10.1161/JAHA.116.003368. PMID: 27146445; PMCID: PMC4889201.

21. Parker PA, Banerjee SC, **Matasar MJ**, Bylund CL, Franco K, Li Y, Levin TT, Jacobsen PB, Astrow AB, Leventhal H, Horwitz S, Kissane DW. Protocol for a cluster randomised trial of a communication skills intervention for physicians to facilitate survivorship transition in patients with lymphoma. BMJ Open. 2016 Jun 28;6(6):e011581. doi: 10.1136/bmjopen-2016-011581. PMID: 27354079; PMCID: PMC4932279.

22. Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, **Matasar MJ**, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Sep 15;128(11):1458-64. doi: 10.1182/blood-2016-03-703470. Epub 2016 Jul 25. PMID: 27458003; PMCID: PMC5025897.

23. Shah GL, Yahalom J, **Matasar MJ**, Verwys SL, Goldman DA, Bantilan KS, Zhang Z, McCall SJ, Moskowitz AJ, Moskowitz CH. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. Br J Haematol. 2016 Nov;175(3):440-447. doi: 10.1111/bjh.14245. Epub 2016 Jul 5. PMID: 27377168; PMCID: PMC5554509.

24. Scordo M, Bhatt V, Hsu M, Omuro AM, **Matasar MJ**, DeAngelis LM, Dahi PB, Moskowitz CH, Giralt SA, Sauter CS. A Comprehensive Assessment of Toxicities in Patients with

Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Biol Blood Marrow Transplant. 2017 Jan;23(1):38-43. doi: 10.1016/j.bbmt.2016.09.024. Epub 2016 Oct 3. PMID: 27713090; PMCID: PMC5518313.

25. Vardhana SA, Sauter CS, **Matasar MJ**, Zelenetz AD, Galasso N, Woo KM, Zhang Z, Moskowitz CH. Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Br J Haematol. 2017 Feb;176(4):591-599. doi: 10.1111/bjh.14453. Epub 2016 Dec 16. PMID: 27982423; PMCID: PMC5556376.

26. van Imhoff GW, McMillan A, **Matasar MJ**, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MDC, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. J Clin Oncol. 2017 Feb 10;35(5):544-551. doi: 10.1200/JCO.2016.69.0198. Epub 2016 Dec 28. PMID: 28029326.

27. Rimner A, Lovie S, Hsu M, Chelius M, Zhang Z, Chau K, Moskowitz AJ, **Matasar M**, Moskowitz CH, Yahalom J. Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience. Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1066-1076. doi: 10.1016/j.ijrobp.2017.01.222. Epub 2017 Feb 1. PMID: 28332991; PMCID: PMC5474094.

28. Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, **Matasar MJ**, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17. PMID: 28314788; PMCID: PMC5541854.

29. Franco K, Shuk E, Philip E, Blanch-Hartigan D, Parker PA, **Matasar M**, Horwitz S, Kissane D, Banerjee SC, Bylund CL. Communication between oncologists and lymphoma survivors during follow-up consultations: A qualitative analysis. J Psychosoc Oncol. 2017 Sep-Oct;35(5):513-530. doi: 10.1080/07347332.2017.1313352. Epub 2017 Mar 30. PMID: 28358241; PMCID: PMC5617774.

30. Chan AT, Plodkowski AJ, Pun SC, Lakhman Y, Halpenny DF, Kim J, Goldburg SR, **Matasar MJ**, Moskowitz CS, Gupta D, Steingart R, Weinsaft JW. Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer. J Cardiovasc Magn Reson. 2017 Oct 12;19(1):76. doi: 10.1186/s12968-017-0390-2. PMID: 29025425; PMCID: PMC5639740.

31. Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, **Matasar M**, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro Oncol. 2017 Oct 1;19(10):1380-1390. doi: 10.1093/neuonc/nox086. PMID: 28472509; PMCID: PMC5596171.

32. Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, McCall SJ, Cadzin BR, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz SM, Kumar A, **Matasar M**, Ni A, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Straus D, Younes A, Zelenetz AD, Moskowitz CH. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017 Nov 16;130(20):2196-2203. doi: 10.1182/blood-2017-06-788877. Epub 2017 Sep 5. PMID: 28874350; PMCID: PMC5691245.

33. Salz T, Zabor EC, de Nully Brown P, Dalton SO, Raghunathan NJ, **Matasar MJ**, Steingart R, Vickers AJ, Svenssen Munksgaard P, Oeffinger KC, Johansen C. Preexisting Cardiovascular

Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. J Clin Oncol. 2017 Dec 1;35(34):3837-3843. doi: 10.1200/JCO.2017.72.4211. Epub 2017 Sep 18. PMID: 28922087; PMCID: PMC5707207.

34. Sauter CS, **Matasar MJ**, Schoder H, Devlin SM, Drullinsky P, Gerecitano J, Kumar A, Noy A, Palomba ML, Portlock CS, Straus DJ, Zelenetz AD, McCall SJ, Miller ST, Courtien AI, Younes A, Moskowitz CH. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood. 2018 Apr 19;131(16):1805-1808. doi: 10.1182/blood-2017-08-802561. Epub 2018 Jan 31. PMID: 29386196; PMCID: PMC5909762.

35. Kumar A, Vardhana S, Moskowitz AJ, Porcu P, Dogan A, Dubovsky JA, **Matasar MJ**, Zhang Z, Younes A, Horwitz SM. Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma. Blood Adv. 2018 Apr 24;2(8):871-876. doi: 10.1182/bloodadvances.2017011916. PMID: 29669753; PMCID: PMC5915998.

36. Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, **Matasar MJ**, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J. 2018 Jun 12;8(6):60. doi: 10.1038/s41408-018-0089-0. PMID: 29895903; PMCID: PMC5997645.

37. Vardhana S, Hamlin PA, Yang J, Zelenetz A, Sauter CS, **Matasar MJ**, Ni A, Yahalom J, Moskowitz CH. Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant. Biol Blood Marrow Transplant. 2018 Oct;24(10):2133-2138. doi: 10.1016/j.bbmt.2018.06.009. Epub 2018 Jun 15. PMID: 29909154; PMCID: PMC7517639.

38. Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, **Matasar MJ**, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18. Erratum in: Lancet Haematol. 2019 Mar;6(3):e121. PMID: 29907552; PMCID: PMC6261436.

39. Parker PA, Banerjee SC, **Matasar MJ**, Bylund CL, Rogers M, Franco K, Schofield E, Li Y, Levin TT, Jacobsen PB, Astrow AB, Leventhal H, Horwitz S, Kissane D. Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: A cluster randomized controlled trial. Cancer. 2018 Dec 1;124(23):4567-4576. doi: 10.1002/cncr.31767. Epub 2018 Oct 18. PMID: 30335188; PMCID: PMC6289801.

40. Borchmann S, Joffe E, Moskowitz CH, Zelenetz AD, Noy A, Portlock CS, Gerecitano JF, Batlevi CL, Caron PC, Drullinsky P, Hamilton A, Hamlin PA Jr, Horwitz SM, Kumar A, **Matasar MJ**, Moskowitz AJ, Owens CN, Palomba ML, Younes A, Straus DJ. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019 May 16;133(20):2121-2129. doi: 10.1182/blood-2018-10-877761. Epub 2019 Feb 15. PMID: 30770396; PMCID: PMC7022227.

41. Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, Palomba MLM, Portlock C, Straus DJ, Noy A, Horwitz SM, Moskowitz A, Hamlin P, Moskowitz CH, **Matasar MJ**, Zelenetz AD, Younes A. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019 May 20;9(6):50. doi: 10.1038/s41408-019-0209-5. PMID: 31110172; PMCID: PMC6527702.

42. Chan AT, Fox J, Perez Johnston R, Kim J, Brouwer LR, Grizzard J, Kim RJ, **Matasar M**, Shia J, Moskowitz CS, Steingart R, Weinsaft JW. Late Gadolinium Enhancement Cardiac Magnetic Resonance Tissue Characterization for Cancer-Associated Cardiac Masses: Metabolic and Prognostic Manifestations in Relation to Whole-Body Positron Emission Tomography. J Am Heart Assoc. 2019 May 21;8(10):e011709. doi: 10.1161/JAHA.118.011709. PMID: 31072171; PMCID: PMC6585339.

43. Sauter CS, Senechal B, Rivière I, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Singh AN, Szenes VZ, Yoo S, Dogan A, Wang Y, Moskowitz CH, Giralt S, **Matasar MJ**, Perales MA, Curran KJ, Park J, Sadelain M, Brentjens RJ. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2019 Aug 15;134(7):626-635. doi: 10.1182/blood.2018883421. Epub 2019 Jul 1. PMID: 31262783; PMCID: PMC6695562.

44. Reyes C, Engel-Nitz NM, DaCosta Byfield S, Ravelo A, Ogale S, Bancroft T, Anderson A, Chen M, **Matasar M**. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer. Oncologist. 2019 Sep;24(9):1209-1218. doi: 10.1634/theoncologist.2018-0018. Epub 2019 Feb 22. PMID: 30796156; PMCID: PMC6738320.

45. Reyes C, Engel-Nitz NM, DaCosta Byfield S, Ravelo A, Ogale S, Bancroft T, Anderson A, Chen M, **Matasar M**. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma. Oncologist. 2019 Sep;24(9):1219-1228. doi: 10.1634/theoncologist.2018-0019. Epub 2019 Feb 26. PMID: 30808814; PMCID: PMC6738303.

46. **Matasar MJ**, Luminari S, Barr PM, Barta SK, Danilov AV, Hill BT, Phillips TJ, Jerkeman M, Magagnoli M, Nastoupil LJ, Persky DO, Okosun J. Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. Oncologist. 2019 Nov;24(11):e1236-e1250. doi: 10.1634/theoncologist.2019-0138. Epub 2019 Jul 25. PMID: 31346132; PMCID: PMC6853118.

47. Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, **Matasar MJ**. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6. PMID: 31693429; PMCID: PMC7032881.

48. Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Gerecitano JF, Hamlin PA, Horwitz SM, Joffe E, Kumar A, **Matasar MJ**, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE, Luminari S, Marcheselli L, Federico M, Younes A. Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. Eur J Cancer. 2020 Feb;126:78-90. doi: 10.1016/j.ejca.2019.12.006. Epub 2020 Jan 8. PMID: 31927165; PMCID: PMC7331469.

49. Latella LE, Rogers M, Leventhal H, Parker PA, Horwitz S, **Matasar MJ**, Bylund CL, Kissane DW, Franco K, Banerjee SC. Fear of cancer recurrence in lymphoma survivors: A descriptive study. J Psychosoc Oncol. 2020 May-Jun;38(3):251-271. doi: 10.1080/07347332.2019.1677840. Epub 2019 Oct 16. PMID: 31617830; PMCID: PMC7159999.

50. Parker PA, Banerjee SC, **Matasar MJ**, Bylund CL, Schofield E, Li Y, Jacobsen PB, Astrow AB, Leventhal H, Horwitz S, Kissane D. Cancer worry and empathy moderate the effect of a survivorship-focused intervention on quality of life. Psychooncology. 2020 Jun;29(6):1012-1018. doi: 10.1002/pon.5371. Epub 2020 Mar 11. PMID: 32128909; PMCID: PMC8327217.

51. Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Soumerai JD, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Kumar A, **Matasar MJ**, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE, Younes A. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020 Jul 17;10(7):74. doi: 10.1038/s41408-020-00340-z. PMID: 32678074; PMCID: PMC7366724.

52. Sermer D, Bobillo S, Dogan A, Zhang Y, Seshan V, Lavery JA, Batlevi C, Caron P, Hamilton A, Hamlin P, Horwitz S, Joffe E, Kumar A, **Matasar M**, Noy A, Owens C, Moskowitz A, Palomba ML, Straus D, von Keudell G, Rodriguez-Rivera I, Falchi L, Zelenetz A, Yahalom J, Younes A. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. Blood Adv. 2020 Jul 28;4(14):3382-3390. doi: 10.1182/bloodadvances.2020001551. PMID: 32722781; PMCID: PMC7391142.

53. Anderson N, Delavar A, Friedman DN, Joseph V, Mubdi N, Oeffinger KC, Sklar CA, Offit K, **Matasar M**, Raghunathan N, Antal Z, Straus D, Walsh M, Latham A, Tonorezos ES. Utilization of clinical genetic counseling among childhood and young adult cancer survivors in a registry trial. J Community Genet. 2020 Oct;11(4):501-504. doi: 10.1007/s12687-020-00478-0. Epub 2020 Jul 16. PMID: 32676930; PMCID: PMC7475134.

54. Sermer D, Batlevi C, Palomba ML, Shah G, Lin RJ, Perales MA, Scordo M, Dahi P, Pennisi M, Afuye A, Silverberg ML, Ho C, Flynn J, Devlin S, Caron P, Hamilton A, Hamlin P, Horwitz S, Joffe E, Kumar A, **Matasar M**, Noy A, Owens C, Moskowitz A, Straus D, von Keudell G, Rodriguez-Rivera I, Falchi L, Zelenetz A, Yahalom J, Younes A, Sauter C. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv. 2020 Oct 13;4(19):4669-4678. doi: 10.1182/bloodadvances.2020002118. PMID: 33002134; PMCID: PMC7556134.

55. Khan N, Feliciano J, Müller K, He M, Tao R, Korol E, Dalal M, Rebeira M, **Matasar M**. Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment. Leuk Lymphoma. 2020 Nov;61(11):2630-2637. doi: 10.1080/10428194.2020.1783443. Epub 2020 Jul 20. PMID: 32684056; PMCID: PMC9175565.

56. Bobillo S, Joffe E, Lavery JA, Sermer D, Ghione P, Noy A, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, **Matasar MJ**, Moskowitz A, Owens CN, Palomba ML, Batlevi CL, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Seshan VE, Younes A. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Blood. 2021 Jan 7;137(1):39-48. doi: 10.1182/blood.2020005112. Erratum in: Blood. 2022 Mar 17;139(11):1772. PMID: 32730585; PMCID: PMC8555387.

57. Joffe E, Leyfman Y, Drill E, Rajeeve S, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, **Matasar MJ**, Kumar A, Batlevi CL, Younes A, Straus DJ. Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. Blood Adv. 2021 Jan 26;5(2):345-351. doi: 10.1182/bloodadvances.2020003213. PMID: 33496731; PMCID: PMC7839366.

58. **Matasar MJ**, Capra M, Özcan M, Lv F, Li W, Yañez E, Sapunarova K, Lin T, Jin J, Jurczak W, Hamed A, Wang MC, Baker R, Bondarenko I, Zhang Q, Feng J, Geissler K, Lazaroiu M, Saydam G, Szomor Á, Bouabdallah K, Galiulin R, Uchida T, Soler LM, Cao A, Hiemeyer F, Mehra A, Childs BH, Shi Y, Zinzani PL. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 May;22(5):678-689. doi: 10.1016/S1470-2045(21)00145-5. Epub 2021 Apr 10. Erratum in: Lancet Oncol. 2021 Jun;22(6):e239. PMID: 33848462.

59. Bobillo S, Joffe E, Sermer D, Mondello P, Ghione P, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, **Matasar MJ**, Batlevi CL, Moskowitz A, Noy A, Owens CN, Palomba ML, Straus D, von Keudell G, Dogan A, Zelenetz AD, Seshan VE, Younes A. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. Blood Cancer J. 2021 Jun 16;11(6):113. doi: 10.1038/s41408-021-00506-3. PMID: 34135307; PMCID: PMC8209097.

60. Dahi PB, Lee J, Devlin SM, Ruiz J, Maloy M, Rondon-Clavo C, Petrlik E, Tamari R, Shah G, Scordo M, **Matasar MJ**, Hamlin PA, Papadopoulos E, Jakubowski AA, Perales MA, Moskowitz CH, Sauter CS, Giralt SA. Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. Blood Adv. 2021 Jun 22;5(12):2608-2618. doi: 10.1182/bloodadvances.2020004167. PMID: 34152404; PMCID: PMC8270665.

61. Kumar A, Casulo C, Advani RH, Budde E, Barr PM, Batlevi CL, Caron P, Constine LS, Dandapani SV, Drill E, Drullinsky P, Friedberg JW, Grieve C, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Joseph A, Khan N, Laraque L, **Matasar MJ**, Moskowitz AJ, Noy A, Palomba ML, Schöder H, Straus DJ, Vemuri S, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. J Clin Oncol. 2021 Jul 10;39(20):2257-2265. doi: 10.1200/JCO.21.00108. Epub 2021 Apr 28. PMID: 33909449.

62. Mehta-Shah N, Lunning MA, Moskowitz AJ, Boruchov AM, Ruan J, Lynch P, Hamlin PA, Leonard J, **Matasar MJ**, Myskowski PL, Marzouk E, Nair S, Sholklapper T, Minnal V, Palomba ML, Vredenburgh J, Kumar A, Noy A, Straus DJ, Zelenetz AD, Schoder H, Rademaker J, Schaffer W, Galasso N, Ganesan N, Horwitz SM. Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts. Am J Hematol. 2021 Oct 1;96(10):1211-1222. doi: 10.1002/ajh.26288. Epub 2021 Jul 29. PMID: 34251048; PMCID: PMC8811706.

63. Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, **Matasar MJ**, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25. PMID: 34170745; PMCID: PMC9851707.

64. **Matasar MJ**, Dreyling M, Leppä S, Santoro A, Pedersen M, Buvaylo V, Fletcher M, Childs BH, Zinzani PL. Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):e886-e894. doi: 10.1016/j.clml.2021.06.021. Epub 2021 Jul 2. PMID: 34389273; PMCID: PMC9407680.

65. Drill E, Qiu A, Shapouri S, To TM, Ravelo A, Schade J, Dawson K, **Matasar M**. Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab. Oncology (Williston Park). 2021 Dec 22;35(12):804-811. doi: 10.46883/2021.25920935. PMID: 35089000.

66. Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, Carter J, Hochberg E, Barnes JA, Hamilton AM, Abramson JS, Batlevi CL, **Matasar MJ**, Noy A, Owens CN, Palomba ML, Kumar A, Takvorian T, Ni A, Choma M, Friedman C, Chadha P, Simkins E, Ruiters J, Sechio S, Portman D, Ramos L, Nolet N, Mahajan N, Martignetti R, Mi J, Scorsune K, Lynch J, McGree B, Hughes S, Grieve C, Roeker LE, Thompson M, Johnson PC, Roshal M, Huang J, Biondo J, Wu Q, Jacob A, Abdel-Wahab O, Zelenetz AD. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021 Dec;8(12):e879-e890. doi: 10.1016/S2352-3026(21)00307-0. PMID: 34826411; PMCID: PMC9326222.

67. Stewart CM, Michaud L, Whiting K, Nakajima R, Nichols C, De Frank S, Hamlin PA Jr, **Matasar MJ**, Gerecitano JF, Drullinsky P, Hamilton A, Straus D, Horwitz SM, Kumar A, Moskowitz CH, Moskowitz A, Zelenetz AD, Rademaker J, Salles G, Seshan V, Schöder H, Younes A, Tsui DWY, Batlevi CL. Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. Clin Cancer Res. 2022 Jan 1;28(1):45-56. doi: 10.1158/1078-0432.CCR-21-2183. Epub 2021 Oct 6. PMID: 34615723; PMCID: PMC8812724.

68. Sehn LH, Hertzberg M, Opat S, Herrera AF, Assouline S, Flowers CR, Kim TM, McMillan A, Ozcan M, Safar V, Salles G, Ku G, Hirata J, Chang YM, Musick L, **Matasar MJ**. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022 Jan 25;6(2):533-543. doi: 10.1182/bloodadvances.2021005794. PMID: 34749395; PMCID: PMC8791582.

69. Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, **Matasar M**, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14. PMID: 34904799.

70. Danilov AV, Magagnoli M, **Matasar MJ**. Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment. Oncologist. 2022 Feb 3;27(1):57-66. doi: 10.1093/oncolo/oyab004. PMID: 35305092; PMCID: PMC8842307.

71. Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, **Matasar MJ**, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16. PMID: 34914545; PMCID: PMC8824395.

72. Sha F, Okwali M, Alperovich A, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Khan N, Kumar A, **Matasar MJ**, Moskowitz AJ, Noy A, Owens C, Palomba LM, Rodriguez-Rivera I, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Schöder H, Seshan VE, Salles G, Younes A, Batlevi CL. Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer J. 2022 Feb 10;12(2):29. doi: 10.1038/s41408-022-00620-w. PMID: 35145059; PMCID: PMC8831497.

73. Pak TK, Dixon BN, Buege MJ, Dao PH, Leary MH, Jarrett JC, Duggan TA, Caron P, Falchi L, Hamlin P, Hamilton A, **Matasar MJ**, Moskowitz A, Noy A, Owens CN, Von Keudell G, Younes A, Zelenetz AD, Kumar A. Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience. Leuk Lymphoma. 2022 Apr;63(4):876-884. doi: 10.1080/10428194.2021.2002318. Epub 2021 Nov 16. PMID: 34784853.

74. Lin RJ, Owens CN, Drill E, Iannotta A, Oliveros M, Schick DL, Noy A, Gerecitano JF, Drullinsky PR, Caron PC, Kumar A, **Matasar MJ**, Moskowitz C, Korc-Grodzicki B, Zelenetz AD, Salles GA, Hamlin PA. Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. Haematologica. 2022 May 1;107(5):1144-1152. doi: 10.3324/haematol.2021.278719. PMID: 34289656; PMCID: PMC9052931.

75. Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, **Matasar MJ**, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2022 May;9(5):e374-e384. doi: 10.1016/S2352-3026(22)00045-X. PMID: 35483398; PMCID: PMC9241484.

76. Budde LE, Sehn LH, **Matasar M**, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5. PMID: 35803286.

77. **Matasar MJ**, Hiemeyer F, Childs BH, Zinzani PL. PI3K inhibitors in haematological malignancies. Lancet Oncol. 2022 Aug;23(8):e365. doi: 10.1016/S1470-2045(22)00332-1. PMID: 35901826.

78. Qualls D, Lam HY, Whiting K, Kumar A, **Matasar M**, Owens C, Nichols C, Espeleta JA, Qiu A, Subzwari S, Biggar E, Seshan V, Salles G, Younes A, Batlevi C. A phase 1 trial of copanlisib

plus ibrutinib in relapsed/refractory mantle cell lymphoma. Blood Adv. 2022 Sep 27;6(18):5262-5266. doi: 10.1182/bloodadvances.2021006555. PMID: 35171976; PMCID: PMC9631700.

79. Salz T, Zabor EC, Brown PN, Dalton SO, Raghunathan NJ, **Matasar MJ**, Steingart R, Hjalgrim H, Specht L, Vickers AJ, Oeffinger KC, Johansen C. Cardiovascular risk factors, radiation therapy, and myocardial infarction among lymphoma survivors. Acta Oncol. 2022 Sep;61(9):1064-1068. doi: 10.1080/0284186X.2022.2107402. Epub 2022 Oct 18. PMID: 36256902; PMCID: PMC9888465.

80. Qualls D, Imber BS, Okwali M, Hamlin PA, Kumar A, Lahoud OB, **Matasar MJ**, Noy A, Owens C, Zelenetz AD, North VS, Schöder H, Dogan A, Salles G, Yahalom J, Falchi L. Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era. Br J Haematol. 2023 Feb;200(4):524-527. doi: 10.1111/bjh.18590. Epub 2022 Dec 9. PMID: 36484627.

81. Qualls D, Noy A, Straus D, **Matasar M**, Moskowitz C, Seshan V, Dogan A, Salles G, Younes A, Zelenetz AD, Batlevi CL. Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with *CREBBP* or *EP300* mutations: an open label phase II study. Leuk Lymphoma. 2023 Mar;64(3):738-741. doi: 10.1080/10428194.2022.2164194. Epub 2023 Jan 15. PMID: 36642966.

82. Zheng S, Gupta K, Goyal P, Nakajima R, Michaud L, Batlevi CL, Hamlin PA, Horwitz S, Kumar A, **Matasar MJ**, Moskowitz AJ, Moskowitz CH, Noy A, Palomba ML, Straus DJ, Von Keudell G, Falchi L, Yahalom J, Zelenetz AD, Younes A, Salles G, Schöder H, Joffe E. Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting. Cancers (Basel). 2023 Mar 14;15(6):1760. doi: 10.3390/cancers15061760. PMID: 36980646; PMCID: PMC10046293.

83. Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CYY, **Matasar MJ**, Gregory GP, Yoon DH, Shadman M, Fay K, Yoon SS, Panizo C, Flinn IW, Johnston A, Bosch F, Sehn LH, Wei MC, Yin S, To I, Li CC, Huang H, Kwan A, Penuel E, Budde EE. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2023 Apr 17:bloodadvances.2022009260. doi: 10.1182/bloodadvances.2022009260. Epub ahead of print. PMID: 37067952.

84. Johnson WT, Ganesan N, Epstein-Peterson ZD, Moskowitz AJ, Stuver RN, Maccaro CR, Galasso N, Chang T, Khan N, Aypar U, Lewis NE, Zelenetz AD, Palomba ML, **Matasar MJ**, Noy A, Hamilton AM, Hamlin PA, Caron PC, Straus DJ, Intlekofer AM, Batlevi CL, Kumar A, Owens CN, Sauter CS, Falchi L, Lue JK, Vardhana SA, Salles GA, Dogan A, Schultz ND, Arcila ME, Horwitz SM. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy. Blood Adv. 2023 Apr 20:bloodadvances.2023009953. doi: 10.1182/bloodadvances.2023009953. Epub ahead of print. PMID: 37078708.

85. **Matasar M**, Alvarez JS, Parise H, Zuk E, Di Maio D, Shapouri S, Lin SW. EE514 A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Third-or Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US). Value in Health. 2023 Jun 1;26(6):S153.

86. Stuver RN, Drill E, Qualls D, Okwali M, Batlevi CL, Caron PC, Dogan A, Epstein-Peterson ZD, Falchi L, Hamlin PA, Horwitz SM, Imber BS, Intlekofer AM, Johnson WT, Khan N, Kumar A, Lahoud OB, Lue JK, **Matasar MJ**, Moskowitz AJ, Noy A, Owens CN, Palomba ML, Schöder H, Vardhana SA, Yahalom J, Zelenetz AD, Salles GA, Straus DJ. Retrospective Characterization of Nodal Marginal Zone Lymphoma. Blood Adv. 2023 Jun 12:bloodadvances.2022009587. doi: 10.1182/bloodadvances.2022009587. Epub ahead of print. PMID: 37307213.

87. Buege MJ, Drill E, Horwitz SM, LeVoir A, Pak T, Peterson TJ, Dao PH, **Matasar MJ**. Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure. Eur J Haematol. 2023 Jul;111(1):96-102. doi: 10.1111/ejh.13971. Epub 2023 Apr 1. PMID: 36971022.

88. Parastoo B. Dahi, Sheila Kenny, Jessica Flynn, Sean M. Devlin, Josel D. Ruiz, Stephanie A. Chinapen, Oscar B. Lahoud, **Matthew J. Matasar**, Craig H. Moskowitz, Miguel-Angel Perales, Gunjan Shah, Craig S. Sauter, Sergio A. Giralt, Alexander I. Geyer & Ann A. Jakubowski (2023) Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma, Leukemia & Lymphoma, DOI: 10.1080/10428194.2023.2256912

89. **Matthew Matasar**, Anthony Masaquel, Rodrigo S. Ho, Aino Launonen, Carmen D. Ng, Rongrong Wang, David Fox, Farah Hossain, Jia Li & John M. Burke (2023) US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma, Journal of Medical Economics, 26:1, 1134-1144, DOI: 10.1080/13696998.2023.2254640

90. John M. Burke et al, Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone, Clinical Lymphoma, Myeloma and Leukemia, https://doi.org/10.1016/j.clml.2023.08.005

91. **Matasar M**, Bartlett N, Shadman M, Budde L, Flinn I, Gregory G, Kim W, Hess G, El-Sharkawi D, Diefenbach C, Huang H, To I, Parreira J, Wu M, Kwan A, Assouline S. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase I/II Trial. Clinical Lymphoma, Myeloma and Leukemia. doi: 10.1016/j.clml.2023.12.005.

92. Ghione P, Ahsanuddin S, Luttwak E, Varela SB, Nakajima R, Michaud L, Gupta K, Navitski A, Straus D, Palomba ML, Moskowitz A, Noy A, Hamlin P, **Matasar M,** Kumar A, Falchi L, Yahalom J, Horwitz S, Zelenetz A, Younes A, Salles G, Schöder H, Joffe E. Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good long-term outcomes. Haematologica. 2023 Aug 31;. doi: 10.3324/haematol.2022.282643. [Epub ahead of print] PubMed PMID: 37646672.

93. **Matthew Matasar** , Nancy L. Bartlett , Mazyar Shadman , Lihua E. Budde , Ian Flinn , Gareth P. Gregory , Won Seog Kim , Georg Hess , Dima El-Sharkawi , Catherine S. Diefenbach , Huang Huang , Iris To , Joana Parreira , Mei Wu , Antonia Kwan , Sarit Assouline , Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell NonHodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase I/II Trial, Clinical Lymphoma, Myeloma and Leukemia (2023), doi: https://doi.org/10.1016/j.clml.2023.12.005

94. **Matasar M,** Bartlett NL, Shadman M, Budde LE, Flinn I, Gregory GP, Kim WS, Hess G, El-Sharkawi D, Diefenbach CS, Huang H, To I, Parreira J, Wu M, Kwan A, Assouline S. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. Clin Lymphoma Myeloma Leuk. 2023 Dec 12:S2152-2650(23)02194-8. doi: 10.1016/j.clml.2023.12.005. Epub ahead of print. PMID: 38195322.

95. Bantilan KS, Smith AN, Maurer MJ, Teruya-Feldstein J, **Matasar MJ,** Moskowitz AJ, Straus DJ, Noy A, Palomba ML, Horwitz SM, Hamlin PA, Portlock CS, Cerhan JR, Habermann TM, Salles GA, Nowakowski GS, Moskowitz CH, Zelenetz AD. Matched control analysis suggests R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared to R-CHOP. Blood Adv. 2024 Jan 25:bloodadvances.2023011408. doi: 10.1182/bloodadvances.2023011408. Epub ahead of print. PMID: 38271621.

96. Lin, SW., Shapouri, S., Parisé, H. et al. Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA. PharmacoEconomics (2024). https://doi.org/10.1007/s40273-024-01358-y

97. Schuster SJ, Huw LY, Bolen CR, Maximov V, Polson AG, Hatzi K, Lasater EA, Assouline SE, Bartlett NL, Budde LE, **Matasar MJ,** Koeppen H, Piccione EC, Wilson D, Wei MC, Yin S, Penuel E. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas. Blood. 2024 Feb 29;143(9):822-832. doi: 10.1182/blood.2023022348. PMID: 38048694.

98. Epstein-Peterson ZD, Drill E, Aypar U, Batlevi CL, Caron P, Dogan A, Drullinsky P, Gerecitano J, Hamlin PA, Ho C, Jacob A, Joseph A, Laraque L, **Matasar MJ**, Moskowitz AJ, Moskowitz CH, Mullins C, Owens C, Salles G, Schöder H, Straus DJ, Younes A, Zelenetz AD, Kumar A. Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation. Haematologica 2024;109(4):1149-1162; https://doi.org/10.3324/haematol.2023.282898.

99. Lihua E. Budde et al. Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. JCO 0, JCO.23.02329. doi:10.1200/JCO.23.02329

100. Flowers CR, **Matasar MJ**, Herrera AF, Hertzberg M, Assouline S, Demeter J, McMillan A, Mehta A, Opat S, Trnňný M, Musick L, Hirata J, Yang A, Sehn LH. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study. Haematologica. 2024 Apr 1;109(4):1194-1205. doi: 10.3324/haematol.2023.283557. PMID: 37767550; PMCID: PMC10985435.

101. Epstein-Peterson ZD, Drill E, Aypar U, Batlevi CL, Caron P, Dogan A, Drullinsky P, Gerecitano J, Hamlin PA, Ho C, Jacob A, Joseph A, Laraque L, **Matasar MJ**, Moskowitz AJ, Moskowitz CH, Mullins C, Owens C, Salles G, Schöder H, Straus DJ, Younes A, Zelenetz AD, Kumar A. Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation. Haematologica. 2024 Apr 1;109(4):1149-1162. doi: 10.3324/haematol.2023.282898. PMID: 37646671; PMCID: PMC10985438.

102. **Matasar, M**., Sanchez Alvarez, J., Parisé, H., Zuk, E., Di Maio, D., Shapouri, S., … Lin, S. W. (2024). Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States. Journal of Medical Economics, 1–36. https://doi.org/10.1080/13696998.2024.2352820

103. Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, **Matasar MJ**, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, Cheah CY, Ma CY, Huang H, Kwan A, Wei MC, Yin S, Bartlett NL. Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. J Clin Oncol. 2024 Jul 1;42(19):2250-2256. doi: 10.1200/JCO.23.02329. Epub 2024 Mar 28. PMID: 38547425; PMCID: PMC11210942.

104. Zinzani PLL, Wang H, Feng J, Kim TM, Tao R, Zhang H, Fogliatto LM, Maluquer Artigal C, Özcan M, Yanez Ruiz EP, Kim WS, Kirtbaya D, Kriachok I, Maciel F, Xue H, Bouabdallah K, Phelps C, Chaturvedi S, Weispfenning A, Morcos PN, Odongo FCA, Buvaylo V, Childs BH, Dreyling M, **Matasar MJ,** Ghione P. CHRONOS-4: Phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma. Blood Adv. 2024 Jul 26:bloodadvances.2024013236. doi: 10.1182/bloodadvances.2024013236. Epub ahead of print. PMID: 39058951.

105. Luo, Y., Wang, Y., Chen, Y., Li, Y., & **Matasar, M.** (2024). Brain-inspired computing and neuromorphic computing: A comparative review. *Brain-inspired cognitive neuroscience*, 100031. https://doi.org/10.1016/j.bneo.2024.100031

106. Pier Luigi Zinzani, Huaqing Wang, Jifeng Feng, Tae Min Kim, Rong Tao, Huilai Zhang, Laura Fogliatto, Clara Maluquer Artigal, Muhit Özcan, Eduardo Yanez, Won Seog Kim, Dmitry Kirtbaya, Iryna Kriachok, Felipe Maciel, Hongwei Xue, Krimo Bouabdallah, Charles Phelps, Shalini Chaturvedi, Anke Weispfenning, Peter N. Morcos, Fatuma Odongo, Viktoriya Buvaylo, Barrett H. Childs, Martin Dreyling, **Matthew Matasar**, Paola Ghione; Chronos-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma. Blood Adv 2024; 8 (18): 4866–4876. doi: https://doi.org/10.1182/bloodadvances.2024013236

107. Gurumurthi, A., Bantilan, K. S., Hamlin, P. A., Kumar, A., **Matasar, M**., Zhu, M., … von Keudell, G. (2024). A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma. Leukemia & Lymphoma, 1–4. https://doi.org/10.1080/10428194.2024.2398658

108. Ghione, P., Bantilan, K. S., Joffe, E., Palomba, M. L., Noy, A., Caron, P., Hamlin, P., Kumar, A., **Matasar, M**. Owens, C. (2024). CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas. Blood Neoplasia, 1(4), 100031. doi: 10.1016/j.bneo.2024.100031

109. Laurie H. Sehn, Nancy L. Bartlett, **Matthew J. Matasar**, Stephen J. Schuster, Sarit E. Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Derrick Kaufman, Antonia Kwan, Elicia Penuel, Christopher R. Bolen, Lihua Elizabeth Budde; Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood 2024; blood.2024025454. doi: https://doi.org/10.1182/blood.2024025454

110. Max S. Topp, **Matthew J. Matasar,** John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi, Yuan Cheng, Dina M. Flink, Min Zhu, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Jennifer L. Crombie; Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: Primary analysis of the ELM-1 study. Blood 2024; blood.2024027044. doi: https://doi.org/10.1182/blood.2024027044

111. Elise A. Chong, Elicia Penuel, Ellen B. Napier, Rachel K. Lundberg, Lihua E. Budde, Mazyar Shadman, **Matthew J. Matasar,** Nancy L. Bartlett, Ian W. Flinn, Francesc Bosch, Keith Fay, Andre Goy, Anita Kumar, Loretta J. Nastoupil, Michael C. Wei, Mei Wu, Shen Yin, Joseph A. Fraietta, Emeline R. Chong, Stephen J. Schuster; Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. *Blood Adv* 2025; 9 (4): 696–703. doi: https://doi.org/10.1182/bloodadvances.2024013640

112. Ferrante JM, Macenat M, Howard J, Patel N, Mahesh J, Bissett M, Peram JJ, Scolleder JD, Grosso M, Hudson SV, O'Malley D, Devine KA, **Matasar M**, Evens AM, Manne SL. Perspectives of lymphoma survivors and oncology care providers on survivorship care: a qualitative study. JCO Oncol Pract. 2025 Feb 20:OP2400742. doi: 10.1200/OP-24-00742. [Epub ahead of print] PubMed PMID: 39977719.

113. St-Pierre, F., Bhatta, S., Doukas, P. G., Jenkin, M., Annunzio, K., Rojek, A. E., Gibson, A., Tiger, Y. K., McCall, B., Alhamad, K., Hansen, A., Alderuccio, J. P., Adewale, O., Patel, K., Trabolsi, A., Lossos, I. S., Fitzgerald, L., Ollila, T. A., **Matasar, M. J.**, Kline, J., … Epperla, N. (2025). Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study. *Blood cancer journal*, *15*(1), 110. https://doi.org/10.1038/s41408-025-01318-5

114. C. R. Miller, Y. Huang, J. N. Allan, et al., " Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era," *American Journal of Hematology* (2025): 1–5, https://doi.org/10.1002/ajh.27760.

115. Steiner, R. E., Nikolaenko, L., Nair, R., Seshan, V. E., Thiruvengadam, S., Khan, N., Abramson, J. S., Horwitz, S. M., **Matasar, M. J.,** Owens, C. N., Rodriguez-Rivera, I. I., Strauss, D., Pardee, T. S., Luther, S., Saboukoulou, S., Thet, W. S., Vemuri, S., & Noy, A. (2025). *Novel devimistat results in complete remissions in heavily pre-treated Burkitt lymphoma in a phase II trial*. *Blood Advances*. Advance online publication. https://doi.org/10.1182/bloodadvances.2025016168

116. Arnason, J. E., **Matasar, M. J.,** Luminari, S., Tucker, D. L., Sun, D., Tao, W., Zhu, Y. O., Kundu, K., Gupta, N. T., Leary, A., Jankovic, V., Ambati, S., Mohamed, H., Chaudhry, A., & Brouwer-Visser, J. (2025). Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL. *Blood Advances*. Advance online publication. https://doi.org/10.1182/bloodadvances.2025016332

117. Tsay, A., **Matasar, M**., Moskowitz, C. S., Scott, J., Oeffinger, K. C., Yu, A. F., Kim, J., Jin, L., Reza, M., Liu, J. E., & Weinsaft, J. W. (2025). Incremental yield of stress perfusion cardiac magnetic resonance over exercise stress echocardiography for detection of myocardial injury in Hodgkin lymphoma survivors: A prospective multimodality imaging

study. *Journal of Cardiovascular Magnetic Resonance, 27,* 101287. https://doi.org/10.1016/j.jocmr.2024.101287

118. Morschhauser, F., Salles, G., Sehn, L. H., Herrera, A. F., Friedberg, J. W., Trněný, M., Lenz, G., Sharman, J. P., Herbaux, C., Burke, J. M., **Matasar, M**., Collins, G. P., Mehta-Shah, N., Oberic, L., Chauchet, A., Jurczak, W., Song, Y., Pinto, A., Rai, S., Izutsu, K., Greil, R., Mykhalska, L., Bergua-Burgués, J. M., Cheung, M. C., Shin, H.-J., Hapgood, G., Munhoz, E., Abrisqueta, P., Gau, J.-P., Jiang, Y., McCall, B., Chohan, S., Sugidono, M., Yan, M., Batlevi, C. L., Tilly, H., & Flowers, C. R. (2025). Five-year outcomes of the POLARIX study comparing Pola-R-CHP and R-CHOP in patients with diffuse large B-cell lymphoma. *Journal of Clinical Oncology*. Advance online publication. https://doi.org/10.1200/JCO.24.01512

119. Franck Morschhauser et al. Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. J Clin Oncol 0, JCO-25-00925. DOI:10.1200/JCO-25-00925

B. Books, Monographs and Chapters

Book Chapters

1. Zablotska LB, **Matasar MJ**, Neugut AI. Second malignancies after radiation treatment and chemotherapy for primary cancers. Oncology: An Evidence-Based Approach. 2006:1939-51. (Chang AE, Ganz PA, Hayes DF, et al., eds.) Springer 2006

2. Tonorezos ES, Baxi SS, Blinder V, Feldman DR, Novetsky Friedman D, **Matasar M**, Salz T, Shahrokni A, Oeffinger KC. American Cancer Society. The American Cancer Society Textbook of Clinical Oncology (Prevention to Survivorship). Hoboken, NJ: WileyBlackwell; 2018

3. **Matasar MJ**, Horwitz S. Peripheral T-cell lymphoma. In Management of Hematologic Malignancy (Cambridge; S. Obrien et al, eds), 2010

4. Lunning M, **Matasar MJ**. Survivorship in Hodgkin Lymphoma. In Hodgkin's Lymphoma, Dr. Nima Rezaei (Ed.), ISBN: 978-953-51-0402-5, 2012.

C. Patents Held: None

D. Other Articles (Reviews, Editorials, etc.) In Journals; Chapters; Books; other Professional Communications

D-1. Editorials

1. **Matasar MJ**, Neugut AI. Epidemiology of anaphylaxis in the United States. Curr Allergy Asthma Rep. 2003 Jan;3(1):30-5. doi: 10.1007/s11882-003-0007-8. PMID: 12542990.

2. **Matasar MJ**, Sundararajan V, Grann VR, Neugut AI. Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy. Drugs Aging. 2004;21(2):113-33. doi: 10.2165/00002512-200421020-00004. PMID: 14960128.

3. **Matasar MJ**, Zelenetz AD. Overview of lymphoma diagnosis and management. Radiol Clin North Am. 2008 Mar;46(2):175-98, vii. doi: 10.1016/j.rcl.2008.03.005. PMID: 18619375.

4. Baxi SS, **Matasar MJ**. State-of-the-art issues in Hodgkin's lymphoma survivorship. Curr Oncol Rep. 2010 Nov;12(6):366-73. doi: 10.1007/s11912-010-0123-2. PMID: 20734173.

5. Salz T, Baxi SS, Raghunathan N, Onstad EE, Freedman AN, Moskowitz CS, Dalton SO, Goodman KA, Johansen C, **Matasar MJ**, de Nully Brown P, Oeffinger KC, Vickers AJ. Are we ready to predict late effects? A systematic review of clinically useful prediction models. Eur J Cancer. 2015 Apr;51(6):758-66. doi: 10.1016/j.ejca.2015.02.002. Epub 2015 Feb 27. PMID: 25736818; PMCID: PMC4518853.

6. Johnson SA, Kumar A, **Matasar MJ**, Schöder H, Rademaker J. Imaging for Staging and Response Assessment in Lymphoma. Radiology. 2015 Aug;276(2):323-38. doi: 10.1148/radiol.2015142088. PMID: 26203705.
7. **Matasar M**, Gupta D. Late cardiac effects of therapy for Hodgkin lymphoma. Clin Oncol. 2016;1:1042.
8. **Matasar MJ**, Word ZH. Advances in the diagnosis and management of lymphoma. Blood and Lymphatic Cancer: Targets and Therapy. 2012 Feb 3:29-55. doi:10.2147/blctt.s15554.
9. **Matasar MJ**. Characteristics and Outcome of Patients with Hodgkin Lymphoma with Early Relapse Following Front-line Escalated BEACOPP Based Chemotherapy: A Report from the Australasian Lymphoma Alliance. Leukemia Lymphoma
10. Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N. A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. Blood Advances. 2021 Feb 23;5(4):984-93. [Paper #ADV-2020002567-T].

D-2. Letters to the Editor

1. **Matasar M**. Land(mark) ahoy: PFS24 in relapsed/refractory diffuse large B-cell lymphoma. Transplant Cell Ther. 2022 Sep;28(9):521-522. doi: 10.1016/j.jtct.2022.08.004. PMID: 36031327.